BETA: Please send your feedback!

Exelixis

NAS:EXEL

Biotechnology

$6.43bn
MID cap
$21.52 (1.41%)
7.9779%
since start of 2019
9.74
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 2
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5

About

Exelixis, Inc. is a biopharmaceutical company. It engages in the developing and commercializing small molecule therapies for the treatment of cancer. The company brands include comertriq and cobimetinib. Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.
website

Headquarters

210 East Grand Avenue
South San Francisco, CA 94080

Executives

Name Title Gender
Peter Lamb, PhD Chief Scientific Officer & Executive VP Male
Gisela M. Schwab, MD Chief Medical Officer & President-Medical Affairs null
Stelios B. Papadopoulos, PhD, MBA Chairman Male
Michael M. Morrissey, PhD President, Chief Executive Officer & Director Male
Corey S. Goodman, PhD Founder Male
Susan Hubbard EVP-Public Affairs & Investor Relations Female
Laura Dillard Vice President-Human Resources Female
Jeffrey J. Hessekiel Secretary, Executive VP & General Counsel Male
Christopher J. Senner, CPA Executive VP, Chief Financial & Accounting Officer Male
William Berg, PhD Senior Vice President-Medical Affairs Male

Mindful Investing Summary

  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint N/A
  • Pollution Prevention N/A
  • Water Conservation N/A
  • Data & Privacy Protection N/A
  • Consumer Health, Wellness & Safety N/A
  • Employee Ownership, Satisfaction, Benefits & Pay N/A
  • Workplace Health and Safety N/A
  • Integrity of Corporate Governance N/A
  • Ethical Practices N/A
  • Usage of Conflict Materials N/A
  • Forced Labor N/A
  • Diversity of Corporate Leadership 2

Exelixis - Competitors and Related Companies

How Exelixis stacks up to its peers in the Biotechnology industry or with competing business segments.

Exelixis

NAS:EXEL

Biotechnology

$6.43bn
MID cap
$21.52 (1.41%)
7.9779%
since start of 2019
9.74
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 2
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5
Loading…